Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05311319
Other study ID # 2021-GZWK-03
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date January 11, 2022
Est. completion date December 2023

Study information

Verified date March 2022
Source Fudan University
Contact Lu Wang, PhD
Phone +86-18121299357
Email w.lr@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single center, non-randomized, open, multi-cohort clinical, exploratory Phase II study, to evaluate the efficacy and safety of HAIC combined with TQB2450 and anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) patients at high risk of recurrence after resection.


Description:

The high incidence of HCC recurrence following liver resection is a serious issue. However, no adjuvant therapy has been widely recognized at present. Interventional therapy and systemic drug therapy are common treatment methods and effective treatment for liver cancer. The combination of multiple drugs may reduce the recurrence in HCC patients with high-risk recurrence. TQB2450 is a humanized monoclonal antibody of programmed death-ligand1 (PD-L1), enabling T cells to restore immune activity and thus enhance the immune response. Anlotinib is a novel multi-target tyrosine kinase inhibitor (TKI) for tumor angiogenesis and proliferative signaling.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date December 2023
Est. primary completion date December 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Eastern Cooperative Oncology Group performance status (ECOG-PS): 0-1; 2. The expected survival is more than 3 months; 3. Histologically or cytologically diagnosed as HCC; 4. After hepatectomy, satisfy any of the following recurrence factors: a) microvascular invasion (MVI); b) Single tumor diameter = 8cm; c) The tumor grew infiltratively, unclear boundary and no complete capsule; d) Multiple tumor nodules =3, or nodules<3 but the diameter of a single tumor is > 3cm; e) With portal vein, hepatic vein or cholangiocarcinoma thrombus; f) tumor ruptured or invaded adjacent organs before surgery. 5. hepatitis B virus (HBV) DNA<2000IU/mL; 6. Liver function status Child-Pugh grade A (=6); 7. The main organs function well. 8. Laboratory inspection met the following criteria: Hemoglobin (Hb) =8.0 g/L, Neutrophils (ANC) = 1.5×10^9/L, Platelet count (PLT) = 60×10^9/L, Total bilirubin (TBIL) =3.0 mg/dL, albumin=28 g/L, Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase= 5.0 ×upper limit of normal, International Prothrombin Standardization Ratio (INR) = 2.3, Thyroid-stimulating hormone (TSH) =upper limit of normal; 9. The woman patients of childbearing age who must agree to take contraceptive methods during the research and within another 6 months after it; who are not in the lactation period and examined as negative in blood serum test or urine pregnancy test within 7 days before the research; The man patients who must agree to take contraceptive methods during the research and within another 6 months after it. 10. Voluntary participation and written informed consent; Exclusion Criteria: 1. History of another malignancy tumor , except for the cured skin basal cell carcinoma and cervical carcinoma in situ) 2. Other adjuvant therapy after surgery, such as targeted drugs, programmed death-1 (PD-1) antibody and other immunotherapy, FOLFOX systemic chemotherapy; 3. The imaging examination showed residual tumor after the surgical resection; 4. Patients with previous liver transplantation or preparation for liver transplantation. 5. Patients who are allergic to components of TQB2450 and anlotinib or pharmaceutical excipients; 6. Received any live attenuated vaccine within 4 weeks of admission or during the study period; 7. Patients with a history of immunodeficiency (or autoimmune disease), or other acquired congenital immunodeficiency diseases. 8. Hypertension which cannot be well controlled by antihypertensive drugs (systolic blood pressure = 150 mmHg or diastolic blood pressure = 100 mmHg). 9. A history of gastrointestinal bleeding within 3 months before enrollment; 10. A history of arterial and venous thrombotic events within 6 months before enrollment, such as cerebrovascular accidents (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep venous thrombosis and pulmonary embolism; 11. Hereditary or acquired hemorrhagic and thrombotic tendencies, such as hemophilia, coagulation dysfunction, thrombocytopenia, hypersplenism, etc. 12. Pts need to long-term anticoagulant therapy; 13. Participated in any other drug clinical studies within 3 months before enrollment; 14. A history of psychotropic substance abuse or drug abuse; 15. Patients with concomitant diseases which could seriously endanger their own safety or could affect the completion of the study according to investigators' judgment;

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
HAIC+TQB2450+Anlotinib
HAIC: FOLFOX for 24hour perfusion chemotherapy. Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. TQB2450: 1200 milligrams (mg) administered intravenously (IV) on Day 1 of each 21-day cycle.

Locations

Country Name City State
China Fudan University Shanghai Cancer Center Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Disease Free Survival (DFS) DFS defined as the time from date of randomization until the date of recurrence or death due to any cause 24 months
Secondary Overall survival (OS) OS defined as the time from date of randomization until the date of death due to any cause 24 months
Secondary Time to recurrence (TTR) TTR defined as the time from date of randomization until the date of recurrence. 24 months
Secondary Safety: adverse events adverse events (AEs) categorized by severity in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0. 24 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06041490 - Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation Phase 2
Terminated NCT03956940 - Analysis of cfDNA in Patients With Hepatocarcinoma and Treated by Sorafenib or Regorafenib N/A
Completed NCT03382327 - Benefit of the Use of 3D Models and Tools in Hepatectomy Planning for Hepatocarcinomas N/A
Recruiting NCT03755739 - Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors Phase 2/Phase 3
Recruiting NCT06028724 - A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
Not yet recruiting NCT03718078 - Robotic Endomicroscopy to Better Define Resection Strategies Applied to Hepatic Surgery N/A
Recruiting NCT05794048 - METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors N/A
Recruiting NCT04435977 - Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma Phase 2
Completed NCT04811898 - A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment Phase 1
Completed NCT05464706 - Study on the Quality of Life (QoL) After Liver Surgery N/A
Completed NCT01411579 - Use of DwI-MR to Predict Chemotherapy Response of Liver Metastases and Hepatocarcinoma N/A
Completed NCT02519075 - 11C-Choline PET/CT and DWI MRI for Response Assessment of HCC Candidate to TARE
Recruiting NCT03356236 - Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation